Human Well-being through Innovative Technology
SKIMS BIO stands for Scientific Korea International Medical Service, a name given by Dr. Mark Swanson during my research days at the Mayo Clinic in the United States—an idea that came to him while fishing on the Mississippi River.
The company was founded to develop and commercialize biomarkers for the early diagnosis and monitoring of childhood asthma, as pulmonary function tests are not feasible in young children.
I have accumulated five years of research experience at the Mayo Clinic, the University of Wisconsin Hospital, and National Jewish Health in Colorado—an internationally renowned hospital specializing in allergy and respiratory diseases. In addition, I have dedicated more than 30 years at Inje University Sanggye Paik Hospital as a specialist in allergy and respiratory medicine, combining clinical practice with research. Drawing on this foundation, my mission is to establish a precision medicine platform in the field of asthma and allergy, and to develop personalized treatments until the day when the suffering from asthma is finally eliminated.
Our research team at SKIMS BIO, which opened Korea's first Asthma & Allergy Center, successfully developed the world's first diagnostic kit for asthma and allergy, receiving manufacturing approval from the Ministry of Food and Drug Safety in 2020. The K-EDN Kit serves as a biomarker that enables timely asthma treatment, thereby increasing the likelihood of a complete cure. In addition, we are advancing the development of diagnostic products to identify viral and allergen triggers of asthma.
In my office hangs a framed calligraphy piece reading 醫昌根盛 (Ui-Chang-Geun-Seong), a phrase left to me by my father: "As a physician, flourish and grow deep roots like a tree." I carry these words in my heart as a guiding principle in all our research and development.
I sincerely ask for your continued interest and support in SKIMS BIO.
Thank you.
주식회사 스킴스바이오 김창근
